Cargando…
Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
BACKGROUND: Our aim was to assess the heterogeneity of high-risk (HR) prostate cancer managed with high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT). METHODS: We identified 547 patients who were treated with modern EBRT from 1997 to 2013, of whom 98% received ADT. W...
Autores principales: | Cagney, Daniel N., Dunne, Mary, O’Shea, Carmel, Finn, Marie, Noone, Emma, Sheehan, Martina, McDonagh, Lesley, O’Sullivan, Lydia, Thirion, Pierre, Armstrong, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539631/ https://www.ncbi.nlm.nih.gov/pubmed/28764689 http://dx.doi.org/10.1186/s12894-017-0250-2 |
Ejemplares similares
-
Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells
por: Madan, Ravi A, et al.
Publicado: (2013) -
Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019) -
Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012) -
Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015) -
Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)